Аннотация:In connection with the emergence of new antibiotic resistant
strains of bacteria in the world, the problem of treatment of sepsis
has become more acute. One of the key tasks in the treatment
of severe sepsis is the ability to remove bacterial endotoxins from
the patient’s bloodstream. A high concentration of bacterial
endotoxins in the human blood disrupts the normal functioning
of the immune system and dramatically worsens the patient’s
condition. The removal of endotoxins is carried out in extracorporeal
therapy procedures using sorbents. Thus, the development
of new effective sorbents for the removal of endotoxin is an
important task. Lysozyme is able to bind with the components of
the surface of a bacterial cell, so we have suggested that a lysozyme
based sorbent can potentially be able to bind bacterial
lipopolysaccharides. The sorbent made by us contains 14–15 mg
of a covalently immobilized lysozyme per 1 g of an insoluble
polysaccharide matrix (cross-linked agarose). This sorbent shows
high efficiency of endotoxin binding from solution: 50 mL of sorbent
can remove up to 88% Escherichia coli endotoxin or 84%
Pseudomonas aeruginosa endotoxin from a 500 mL solution with
an endotoxin concentration of 500 EU / mL (50 ng / mL).